Malignant mesothelioma (MM) is an aggressive malignancy of the pleural and peritoneal surfaces. Australia has the highest reported national incidence of mesothelioma in the world, and rates are increasing (Leigh et al., 2002). The clinical outcome for patients with this disease is extremely poor, with median survival of 9 to 12 months (Rizzo et al., 2001; Carbone et al., 2002). The latest developments in chemotherapy, radiotherapy and radical surgery have done little to improve the overall survival rate (Kindler 2000; Zellos et al., 2002). New approaches to therapy are thus required (Nowak et al., 2002). Cancer therapy using conditionally replicative adenoviruses (CRAds) and attenuated measles virus (vaccine strain MV-Edm) are novel and promising approaches to cancer treatment. CRAds strategy relies on selective viral replication in tumour cells but not normal cells. Major efforts have been directed toward achieving selective replication by the deletion of viral functions dispensable in tumour cells or by the regulation of viral genes with tumour-specific promoters (Alemany et al., 2000). However, the major clinical limitation of viral therapy has been lack of efficacy rather than safety concerns. In this study, I constructed CRAds in which tumour-specific promoter for Flt-1 (vascular endothelial growth factor receptor) control the essential E1 gene expression, and evaluated the cell-killing efficacy and specificity of CRAds driven by VEGF and Flt-1 promoters in the number of established mesothelioma cell lines and actual primary tumour cells from patients. CRAds with either VEGF or flt-1 promoters showed a strong killeg effect on mesothelioma cells. Co-delivery of CRAds with MMP-9 (matrix metalloproteinase-9) was assessed to determine whether therapeutic efficacy could be improved by reducing tumourassociated fibrosis thereby enhancing viral spread through a tumour mass. Combined therapy did result in greater suppression of tumour growth in vivo. I also identified an immuno-competent murine model of mesothelioma that was permissive for adenoviral replication. Combined viral therapy with immunotherapy (FGK45, an anti-CD40 antibody) in this model resulted in greater effect than Adwt or FGK45 alone and in greatest survival. I evaluated the capacity of MV-Edm to infect human mesothelioma cells to form syncytia, and lead to apoptosis and cell death. I also assessed the mode of death by analysis of markers of apoptosis including caspase-3. In vivo study showed that MVEdm- GFP transduction could be detected in human xenografts in immune deficient mice. Further studies to evaluate the mechanisms and efficacy of anti-tumour immune stimulation induced by tumour cell killing with CRAds and MV-Edm will be discussed in this study. MV-Edm has good killing effect on mesothelioma cells in vitro. In summary the work presented herein provide new insights into stratgies to improve viral therapies for mesothelioma. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1342596 / Thesis (Ph.D.) - University of Adelaide, School of Medicine, 2008

Thesis (Ph. D.)--Ohio State University, 2008. / Title from first page of PDF file. Includes bibliographical references (p. 111-129).

No description available.

No description available.

La macroautophagie, appelée ici autophagie, est un processus de dégradation lysosomale qui joue un rôle clé dans l'immunité en dégradant des micro-organismes intracellulaires mais également en activant des réponses immunitaires. Cependant, de nombreux virus ont développé des stratégies pour inhiber, utiliser voire détourner l'autophagie à leur propre bénéfice. L'objectif de cette thèse a été d'analyser la place de l'autophagie dans l'infection par le virus de la rougeole (VR). Ce travail démontre que les souches atténuées du VR utilisent plusieurs voies moléculaires successives d'induction d'autophagie dans les cellules infectées. En effet, elles sont capables d'induire une première vague d'autophagie très précoce mais transitoire par l'engagement de l'une des isoformes de leur récepteur d'entrée CD46. Après un bref retour à l'état basal, une deuxième vague d'autophagie est induite par l'interaction de la protéine virale non structurale C avec la protéine cellulaire autophagique IRGM. La formation de syncytia conduit à une troisième voie d'induction d'autophagie qui permet de maintenir l'autophagie mise en place. Cette autophagie soutenue est exploitée par le VR afin de limiter la mort des cellules infectées, ce qui promeut la production de particules virales. Les souches virulentes du VR, incapables de lier CD46, et utilisant comme récepteur d'entrée la protéine CD150, n'induisent que l'autophagie tardive qui est également utilisée pour favoriser la production de particules virales infectieuses. Ce travail de thèse montre donc que l'induction d'une autophagie soutenue lors de l'infection par le VR promeut l'infection, principalement en limitant la mort cellulaire / Macroautophagy, thereafter referred to as autophagy, is a lysosomal degradation which plays a key role in immunity by directly degrading intracellular pathogens but also by favouring innate and adaptive immune responses. However, several viruses have evolved strategies to inhibit, exploit or even hijack autophagy for their own benefit. The aim of this thesis was to analyse the role of autophagy in the course of measles virus (MeV) infection. This work demonstrates that attenuated strains of MeV induce successive autophagy signalling in infected cells, via distinct and uncoupled molecular pathways. First, attenuated MeV strains are able to induce a first early and transient wave of autophagy through the engagement of one of the isoform of their cellular receptor CD46. Soon after infection, a new autophagy signalling is initiated by the interaction of the non-structural MeV protein C with the cellular autophagic protein IRGM. Strikingly, this second autophagy signalling can be sustained overtime within infected cells via a third autophagy input resulting from cell-cell fusion and the formation of syncytia. Sustained autophagy is exploited by MeV to limit the death of infected cells and to improve infectious viral particle formation. Interestingly, virulent strains of MeV, which do not use CD46 as a cellular receptor but use CD150, are unable to induce the early autophagy wave, whereas they induce and exploit the late and sustained autophagy. Thus, this work demonstrates that the induction of a sustained autophagy during MeV infection promotes infectivity, mostly by limiting cell death. Overall, this work describes an unusual and complex interplay between autophagy and MeV

La macroautophagie assure l'homéostasie cellulaire en recyclant du matériel cytosolique obsolète ou délétère et sa dérégulation est associée à plusieurs pathologies. Elle constitue aussi un mécanisme de défense car elle peut éliminer des pathogènes intracellulaires. L'étape cruciale de l'autophagie est la maturation lors de laquelle la vésicule renfermant des substrats cytosoliques, l'autophagosome, fusionne avec des lysosomes et la dégradation a lieu. Nous nous intéressons à la régulation de l'autophagie et aux conséquences de sa perturbation lors des infections, notamment par le virus de la rougeole (VR). Les données de l'équipe montrent qu'il induit et utilise toutes les étapes de l'autophagie, afin de se répliquer efficacement. Mes travaux montrent que des protéines du virus peuvent interagir avec au moins deux protéines cellulaires NDP52 et T6BP qui sont des récepteurs autophagiques (protéines cytosoliques ayant un domaine de liaison aux autophagosomes et un domaine de liaison au substrat à dégrader, par exemple des pathogènes). J'ai alors étudié le rôle des récepteurs autophagiques T6BP, NDP52 et Optineurine dans la réplication virale. J'ai aussi participé à une étude décrivant que NDP52 et Optineurine régulent en plus la maturation. Mes travaux de thèse démontrent un tel double rôle pour T6BP. Cependant, seuls T6BP et NDP52 sont nécessaires à la réplication du VR bien qu'elle requiert la maturation autophagique. Ainsi mes résultats suggèrent d'une part que les trois récepteurs puissent réguler la maturation d'autophagosomes distincts.D'autre part, le VR pourrait exploiter individuellement les autophagosomes dont la maturation dépend de T6BP et NDP52 pour se répliquer / Macroautophagy ensures cell homeostasis through the recycling of obsolete or deleterious cytosolic components and its deregulation is associated with several pathologies. It is also a defense mechanism as it allows the elimination of intracellular pathogens. The most important autophagic step is maturation, during which the cytosolic substrate-containing vesicle, the autophagosome, fuses with lysosomes and the degradation occurs. We study autophagy regulation and the consequences of its disruption during infections and in particular by measles virus (MeV). Our team has shown that MeV induces and exploits all steps of autophagy, to replicate more efficiently. My results indicate that viral proteins can interact with at least two cellular proteins, NDP52 and T6BP, which are autophagy receptors (cytosolic proteins that carry an autophagosome-binding domain and a domain binding substrates that would be degraded, such as intracellular pathogens). I then studied the role of autophagic receptors T6BP, NDP52 and OPTINEURIN in viral replication. I also took part in a study describing NDP52 and OPTINEURIN as autophagosome maturation regulators. My work depicts the same dual role for T6BP. However, only T6BP and NDP52 are necessary for MeV replication even though it requires autophagosome maturation. Thus, my results suggest that the three autophagy receptors might regulate distinct autophagosome maturation on one hand. On the other, MeV could individually exploit autophagosomes, the maturation of which is regulated by T6BP or NDP2 to replicate efficiently

Le virus de la rougeole est un agent pathogène responsable d’immunosuppressions transitoires mais sévères chez les individus infectés. L’infection par ce virus peut ainsi mener à l’établissement d’infections secondaires opportunistes, souvent décrites chez les patients rougeoleux. Cependant, la contribution du virus de la rougeole sur des infections secondaires à l’échelle de la cellule co-infectée n’a jamais fait l’objet d’études. Notre équipe à précédemment démontré que le virus de la rougeole induit une autophagie productive dans les cellules infectées, requise pour une réplication optimale du virus. À l’opposé, certains pathogènes comme la bactérie Salmonella typhimurium sont restreints par l’autophagie. Le but de cette thèse est d’étudier la contribution de l’autophagie sur la prolifération bactérienne en condition de co-infection avec le virus de la rougeole. Au cours du projet, nous avons identifié que dans les cellules co-infectées avec le virus de la rougeole, la bactérie Salmonella typhimurium hyperprolifère. Cette prolifération intense prend place essentiellement dans des cellules multinucléées géantes (syncytia) formées par le virus. En outre, la bactérie, normalement localisée dans une vacuole cellulaire, se localise dans le cytosol de ces syncytia et semble insensible à l’autophagie. Au cours de cette thèse, nous avons identifié que le facteur antimicrobien TBK1 pourrait être détourné par l’infection virale, contribuant ainsi à l’échappement de la bactérie à l’autophagie. Ce travail de thèse met ainsi en évidence une nouvelle possibilité d’échappement de bactéries à l’autophagie lors d’une co-infection virale. / Measles virus is a pathogenic agent responsible for transient but severe immunosuppression in infected individuals. The infection can lead to the establishment of secondary infections, frequently described in measles virus infected patients. Nevertheless, Measles virus contribution to secondary infection at cell scale level have never been studied yet. Our team has previously described that Measles virus induce a fully functional autophagy in infected cells, which is mandatory for an efficient viral replication. On the opposite, some pathogens, as the bacteria Salmonella typhimurium are restricted by autophagy. The aim of this PhD project is to study the contribution of autophagy on bacterial proliferation upon Measles virus co-infection at cell level. During this project, we have identified that in Measles virus coinfected cells, Salmonella typhimurium hyperproliferates. This exacerbated proliferation takes place in multinucleated giant cells induced by the virus, which are called syncytia. In addition, the bacteria, which is normally localized in cellular vacuole, is localized directly inside the cytosol of syncytia. Furthermore, cytosolic bacteria appears to be insensitive to autophagy. During this PhD project, we have identified that the cellular factor TBK1 could be hijack by the viral infection. Thus, this could allow the auophagic escape of the bacteria. This study highlight a new opportunity of autophagic escape of bacteria during a viral co-infection.

abstract: Measles is a contagious, vaccine-preventable disease that continues to be the leading cause of death in children younger than the age of 5 years. While the introduction of the Measles, Mumps, and Rubella vaccine (MMR) has significantly decreased morbidity and mortality rates worldwide, vaccine coverage is highly variable across global regions. Current diagnostic methods rely on enzyme immunoassays (EIA) to detect IgM or IgG Abs in serum. Commercially available Diamedix Immunosimplicity® Measles IgG test kit has been shown to have 91.1% sensitivity and 93.8% specificity, with a positive predictive value of 88.7% and a negative predictive value of 90.9% on the basis of a PRN titer of 120. There is an increasing need for rapid screening for measles specific immunity in outbreak settings. This study aims to develop a rapid molecular diagnostic assay to detect IgG reactive to three individual measles virus (MeV) proteins. Measles virus (MeV) genes were subcloned into the pJFT7_nGST vector to generate N- terminal GST fusion proteins. Single MeV cistrons were expressed using in vitro transcription/translation (IVTT) with human cell lysate. Expression of GST-tagged proteins was measured with mouse anti-GST mAb and sheep anti-mouse IgG. Relative light units (RLUs) as luminescence was measured. Antibodies to MeV antigens were measured in 40 serum samples from healthy subjects. Protein expression of three MeV genes of interest was measured in comparison with vector control and statistical significance was determined using the Student’s t-test (p<0.05). N expressed at the highest level with an average RLU value of 3.01 x 109 (p<0.001) and all proteins were expressed at least 50% greater than vector control (4.56 x 106 RLU). 36/40 serum samples had IgG to N (Ag:GST ratio>1.21), F (Ag:GST ratio>1.92), or H (Ag:GST ratio> 1.23). These data indicate that the in vitro expression of MeV antigens, N, F, and H, were markedly improved by subcloning into pJFT7_nGST vector to generate N-terminal GST fusion proteins. The expression of single MeV genes N, F and H, are suitable antigens for serologic capture analysis of measles-specific antibodies. These preliminary data can be used to design a more intensive study to explore the possibilities of using these MeV antigens as a diagnostic marker. / Dissertation/Thesis / Masters Thesis Biology 2016

abstract: Despite the approval of a Dengue virus (DV) vaccine in five endemic countries, dengue prevention would benefit from an immunization strategy highly immunogenic in young infants and not curtailed by viral interference. Problematically, infants younger than 9 year of age, whom are particularly prone to Dengue severe infection and death, cannot be immunized using current approved DV vaccine. The most important issues documented so far are the lack of efficiency and enhancement of the disease in young seronegative recipients, as well as uneven protection against the four DV serotypes. Based on data from clinical trials that showed enhanced performance of dengue vaccines when the host has previous anti-flaviviral immunity, I proposed here an attractive solution to complement the current vaccine: a recombinant measles vaccine vectoring dengue protective antigens to be administered to young infants. I hypothesized that recombinant measles virus expressing Dengue 2 and 4 antigens would successfully induce neutralizing responses against DV2 and 4 and the vaccine cocktail of this recombinant measles can prime anti-flaviviral neutralizing immunity. For this dissertation, I generated and performed preclinical immune assessment for four novel Measles-Dengue (MV-DV) vaccine candidates. I generated four MVs expressing the pre membrane (prM) and full length or truncated (90%) forms of the major envelope (E) from DV2 and DV4. Two virus, MVvac2-DV2(prME)N and MVvac2-DV4(prME), expressed high levels of membrane associated full-length E, while the other two viruses, MVvac2-DV2(prMEsol)N and MVvac2-DV4(prMEsol)N, expressed and secreted truncated, soluble E protein to its extracellular environment. The last two vectored vaccines proved superior anti-dengue neutralizing responses comparing to its corresponding full length vectors. Remarkably, when MVvac2-DV2/4(prMEsol)N recombinant vaccines were combined, the vaccine cocktail was able to prime cross-neutralizing responses against DV 1 and the relatively distant 17D yellow fever virus attenuated strain. Thus, I identify a promising DV vaccination strategy, MVvac2-DV2/4(prMEsol)N, which can prime broad neutralizing immune responses by using only two of the four available DV serotypes. The current MV immunization scheme can be advantageus to prime broad anti-flaviviral neutralizing immunity status, which will be majorly boosted by subsequent chimeric Dengue vaccine approaches. / Dissertation/Thesis / Doctoral Dissertation Microbiology 2016

Die subakute sklerosierende Panenzephalitis (SSPE), eine durch das Masernvirus (MV) verursachte sogenannte „ slow virus “ Infektion des zentralen Nervensystems, ist eine progrediente chronische Erkrankung, die zum Tod führt und bisher medikamentös nicht heilbar ist. Da die RNAi-Strategien grundsätzlich zur Inhibition von Viren in Säugetierzellen geeignet sind, stellt die RNAi eine Möglichkeit dar, die Infektion auf molekularer Ebene anzugreifen. Dafür wurden verschiedene miRNA-Expressionskassetten, welche gegen zwei Sequenzen im MV- Hämagglutinin-Gen (H) und sechs Sequenzen im MV-Nukleokapsid-Gen (N) gerichtet sind, konstruiert und in MV infizierte Zellen eingebracht. Diese miRNAExpressionskassetten wurden auf zwei verschiedenen Wegen in die Zelle eingebracht: Zum einen wurden sie über ein miRNA-Expressionsplasmid (pmiR), welches in die Zellen transfiziert wird, transient exprimiert; zum anderen wurden sie durch virale Vektoren (HIV, SIV und MoMLV) stabil in die Zellen transduziert. Dies ermöglicht die Integration der miRNAExpressionskassette in das Genom der Zelle und dadurch die Expression der miRNAs für einige Wochen. In erster Linie zielt die Wirkung der RNA-Interferenz auf die Degradierung der spezifischen MV-mRNAs. Diese Degradierung konnte mit Hilfe quantitative Reverse Transkription real time-PCR (qRT-PCR) nachgewiesen werden. Die transiente Expression der verschiedenen miRNAs gegen das MV-N-Gen bzw. MV-H-Gen führte in jedem Fall zu einer Reduktion der viralen genspezifischen mRNAs. Die Reduktion der MV spezifischen mRNA betrug 99,8% für das MV-N-Gen und 91,2% für das MV-H-Gen. Die Wirkung der RNA-Interferenz zielt am Ende auf die Reduktion der neu gebildeten infektiösen Viruspartikel und ihrer Verbreitung in der Zellkultur, welche die spezifische miRNA gegen MV-N oder MV-H exprimiert. Dieser Effekt konnte nur durch Plaque-Assay überprüft werden. Die Plaque-Assays, die mit den Überständen der miRNA-behandelten Zelllinien durchgeführt wurden, zeigten ebenfalls eine Reduktion der neu gebildeten infektiösen MV-Partikeln von 97,6% für die miRNA gegen das MV-H-Gen und 99,0 % für die miRNA gegen das MV-N-Gen. Die intrazelluläre Expression der miRNAs führte zu einer Hemmung der Virus-Ausbreitung in MV-infizierten Zellen. Die Reduktion betrug hier durch die Expression der miRNA-N10 98,8% und durch die Expression der miRNA-H2 80,0%. Hier zeigte sich, dass die Inhibition der viralen Proteinsynthese durch den RNAi-Mechanismus auch die Verbreitung der MVInfektion durch Zell-Zell-Fusion behindern kann. Dies zeigte sich durch die verringerte Bildung von Plaques bzw. Synzytien in miRNA-behandelten Zelllinien. Die vorliegende Arbeit zeigte, dass RNAi effektive gegen MV-Infektion in Zellkultur eingesetzt werden kann. Als nächster Schritt sollte daher dieser RNAi-Effekt im etablierten Tiermodell ausgetestet werden.